<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002042</url>
  </required_header>
  <id_info>
    <org_study_id>004F</org_study_id>
    <secondary_id>87-022</secondary_id>
    <nct_id>NCT00002042</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ortho Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of r-HuEPO administration to patients with AIDS or&#xD;
      advanced AIDS related complex (ARC) and anemia secondary to their disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <condition>Cytopenias</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  History of any primary hematologic disease.&#xD;
&#xD;
          -  HIV disease related dementia.&#xD;
&#xD;
          -  Uncontrolled hypertension (diastolic blood pressure &gt; 100 mmHg).&#xD;
&#xD;
          -  Presence of concomitant iron deficiency.&#xD;
&#xD;
          -  Anemia attributable to factors other than HIV disease or zidovudine (AZT) therapy.&#xD;
&#xD;
          -  Acute opportunistic infection.&#xD;
&#xD;
          -  History of seizures.&#xD;
&#xD;
          -  Clinically significant disease / dysfunction of the pulmonary, cardiovascular,&#xD;
             endocrine, neurologic, gastrointestinal, or genitourinary systems not attributable to&#xD;
             underlying HIV disease.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine (AZT) therapy during the double-blind phase of study.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  History of any primary hematologic disease.&#xD;
&#xD;
          -  Clinically significant disease / dysfunction of the pulmonary, cardiovascular,&#xD;
             endocrine, neurologic, gastrointestinal, or genitourinary systems not attributable to&#xD;
             underlying HIV disease.&#xD;
&#xD;
          -  HIV disease related dementia.&#xD;
&#xD;
          -  Uncontrolled hypertension (diastolic blood pressure &gt; 100 mmHg).&#xD;
&#xD;
          -  Presence of concomitant iron deficiency.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Experimental drug or experimental device.&#xD;
&#xD;
          -  Cytotoxic chemotherapy.&#xD;
&#xD;
          -  Excluded within 2 months of study entry:&#xD;
&#xD;
          -  Androgen therapy.&#xD;
&#xD;
          -  Zidovudine (AZT) therapy and during the double-blind phase.&#xD;
&#xD;
        Clinical diagnosis with AIDS or AIDS related complex (ARC) and related anemia.&#xD;
&#xD;
          -  Clinical diagnosis of AIDS or ARC.&#xD;
&#xD;
          -  Clinically stable for 1 month preceding study entry.&#xD;
&#xD;
          -  Patients should preferably be transfusion dependent.&#xD;
&#xD;
        Substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ortho Pharmaceutical Corp</name>
      <address>
        <city>Raritan</city>
        <state>New Jersey</state>
        <zip>088690602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 1989</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Recombinant Proteins</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Anemia</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

